Repligen Co. (NASDAQ:RGEN) Shares Purchased by NBW Capital LLC

NBW Capital LLC lifted its holdings in Repligen Co. (NASDAQ:RGEN) by 8.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,038 shares of the biotechnology company’s stock after acquiring an additional 2,650 shares during the period. NBW Capital LLC owned approximately 0.06% of Repligen worth $5,940,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale increased its position in shares of Repligen by 1.5% in the third quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock worth $1,663,000 after acquiring an additional 159 shares in the last quarter. International Assets Investment Management LLC boosted its stake in shares of Repligen by 18,449.1% in the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after purchasing an additional 58,299 shares during the period. American Century Companies Inc. boosted its stake in shares of Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the period. Louisiana State Employees Retirement System purchased a new position in shares of Repligen in the fourth quarter valued at $2,625,000. Finally, Atria Investments Inc purchased a new position in shares of Repligen in the third quarter valued at $1,046,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 in the last ninety days. 1.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on RGEN shares. KeyCorp upped their target price on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Finally, Stifel Nicolaus increased their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $4.38 on Thursday, reaching $156.60. 462,124 shares of the company’s stock were exchanged, compared to its average volume of 534,642. The firm has a market capitalization of $8.74 billion, a price-to-earnings ratio of 219.36, a PEG ratio of 5.38 and a beta of 1.02. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The business’s 50-day moving average is $190.02 and its two-hundred day moving average is $173.20. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm’s revenue was down 16.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.68 earnings per share. As a group, equities research analysts forecast that Repligen Co. will post 1.46 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.